

Mark Nellist

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7635727/publications.pdf>

Version: 2024-02-01

49
papers

6,225
citations

186265
28
h-index

189892
50
g-index

52
all docs

52
docs citations

52
times ranked

5137
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of the Tuberous Sclerosis Gene TSC1 on Chromosome 9q34. <i>Science</i> , 1997, 277, 805-808.	12.6	1,550
2	Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013, 49, 243-254.	2.1	1,185
3	Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013, 49, 255-265.	2.1	693
4	Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease "a contiguous gene syndrome. <i>Nature Genetics</i> , 1994, 8, 328-332.	21.4	466
5	Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype " phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. <i>European Journal of Human Genetics</i> , 2005, 13, 731-741.	2.8	405
6	Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. <i>Modern Pathology</i> , 2014, 27, 1321-1330.	5.5	174
7	Characterization of the Cytosolic Tuberin-Hamartin Complex. <i>Journal of Biological Chemistry</i> , 1999, 274, 35647-35652.	3.4	164
8	Clinicopathological and immunohistochemical findings in an autopsy case of tuberous sclerosis complex. <i>Neuropathology</i> , 2008, 28, 577-590.	1.2	96
9	Unusually mild tuberous sclerosis phenotype is associated with TSC2R905Q mutation. <i>Annals of Neurology</i> , 2006, 60, 528-539.	5.3	82
10	Distinct effects of single amino-acid changes to tuberin on the function of the tuberin " hamartin complex. <i>European Journal of Human Genetics</i> , 2005, 13, 59-68.	2.8	73
11	Functional assessment of variants in the <i>TSC1</i> and <i>TSC2</i> genes identified in individuals with Tuberous Sclerosis Complex. <i>Human Mutation</i> , 2011, 32, 424-435.	2.5	73
12	TORC1-dependent epilepsy caused by acute biallelic <i>Tsc1</i> deletion in adult mice. <i>Annals of Neurology</i> , 2013, 74, 569-579.	5.3	68
13	Comparative Analysis and Genomic Structure of the Tuberous Sclerosis 2 (TSC2) Gene in Human and Pufferfish. <i>Human Molecular Genetics</i> , 1996, 5, 131-137.	2.9	66
14	G3BPs tether the TSC complex to lysosomes and suppress mTORC1 signaling. <i>Cell</i> , 2021, 184, 655-674.e27.	28.9	65
15	Alternative Splicing of the Tuberous Sclerosis 2 (TSC2) Gene in Human and Mouse Tissues. <i>Genomics</i> , 1995, 27, 475-480.	2.9	64
16	Identification and Characterization of the Interaction between Tuberin and 14-3-3 η . <i>Journal of Biological Chemistry</i> , 2002, 277, 39417-39424.	3.4	64
17	Targeted Next Generation Sequencing reveals previously unidentified TSC1 and TSC2 mutations. <i>BMC Medical Genetics</i> , 2015, 16, 10.	2.1	62
18	Functional Assessment of <i>TSC2</i> Variants Identified in Individuals with Tuberous Sclerosis Complex. <i>Human Mutation</i> , 2013, 34, 167-175.	2.5	60

#	ARTICLE	IF	CITATIONS
19	Subependymal giant cell astrocytomas in Tuberous Sclerosis Complex have consistent <i>TSC1/TSC2</i> biallelic inactivation, and no <i>BRAF</i> mutations. <i>Oncotarget</i> , 2017, 8, 95516-95529.	1.8	49
20	Functional assessment of TSC1 missense variants identified in individuals with tuberous sclerosis complex. <i>Human Mutation</i> , 2012, 33, 476-479.	2.5	45
21	Germline activating AKT3 mutation associated with megalencephaly, polymicrogyria, epilepsy and hypoglycemia. <i>Molecular Genetics and Metabolism</i> , 2015, 114, 467-473.	1.1	42
22	PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex. <i>Scientific Reports</i> , 2015, 5, 14534.	3.3	40
23	Structure of the TBC1D7-TSC1 complex reveals that TBC1D7 stabilizes dimerization of the TSC1 C-terminal coiled coil region. <i>Journal of Molecular Cell Biology</i> , 2016, 8, 411-425.	3.3	37
24	Genotype and brain pathology phenotype in children with tuberous sclerosis complex. <i>European Journal of Human Genetics</i> , 2016, 24, 1688-1695.	2.8	35
25	Phosphorylation and binding partner analysis of the TSC1-TSC2 complex. <i>Biochemical and Biophysical Research Communications</i> , 2005, 333, 818-826.	2.1	33
26	Identification of Regions Critical for the Integrity of the TSC1-TSC2-TBC1D7 Complex. <i>PLoS ONE</i> , 2014, 9, e93940.	2.5	32
27	TSC2 N-terminal lysine acetylation status affects to its stability modulating mTORC1 signaling and autophagy. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 2658-2667.	4.1	31
28	Structural Basis of the Interaction between Tuberous Sclerosis Complex 1 (TSC1) and Tre2-Bub2-Cdc16 Domain Family Member 7 (TBC1D7). <i>Journal of Biological Chemistry</i> , 2016, 291, 8591-8601.	3.4	31
29	Identification of a region required for TSC1 stability by functional analysis of TSC1 missense mutations found in individuals with tuberous sclerosis complex. <i>BMC Medical Genetics</i> , 2009, 10, 88.	2.1	29
30	Preliminary Functional Assessment and Classification of <i>DEPDC5</i> Variants Associated with Focal Epilepsy. <i>Human Mutation</i> , 2015, 36, 200-209.	2.5	28
31	RHEB/mTOR hyperactivity causes cortical malformations and epileptic seizures through increased axonal connectivity. <i>PLoS Biology</i> , 2021, 19, e3001279.	5.6	27
32	A reliable cell-based assay for testing unclassified TSC2 gene variants. <i>European Journal of Human Genetics</i> , 2009, 17, 301-310.	2.8	26
33	Central TSC2 missense mutations are associated with a reduced risk of infantile spasms. <i>Epilepsy Research</i> , 2013, 103, 83-87.	1.6	26
34	Missense mutations to the TSC1 gene cause tuberous sclerosis complex. <i>European Journal of Human Genetics</i> , 2009, 17, 319-328.	2.8	25
35	TSC1 binding to lysosomal PIPs is required for TSC complex translocation and mTORC1 regulation. <i>Molecular Cell</i> , 2021, 81, 2705-2721.e8.	9.7	25
36	Analysis of TSC1 truncations defines regions involved in TSC1 stability, aggregation and interaction. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 774-781.	3.8	23

#	ARTICLE	IF	CITATIONS
37	Comparison of the functional and structural characteristics of rare <i>TSC2</i> variants with clinical and genetic findings. <i>Human Mutation</i> , 2020, 41, 759-773.	2.5	22
38	Examination of the genetic factors underlying the cognitive variability associated with neurofibromatosis type 1. <i>Genetics in Medicine</i> , 2020, 22, 889-897.	2.4	21
39	The TSC1-TSC2 complex consists of multiple TSC1 and TSC2 subunits. <i>BMC Biochemistry</i> , 2012, 13, 18.	4.4	20
40	Structure of the TSC2 GAP Domain: Mechanistic Insight into Catalysis and Pathogenic Mutations. <i>Structure</i> , 2020, 28, 933-942.e4.	3.3	20
41	Functional characterisation of the TSC1-TSC2 complex to assess multiple TSC2 variants identified in single families affected by tuberous sclerosis complex. <i>BMC Medical Genetics</i> , 2008, 9, 10.	2.1	17
42	Variants Within <i>TSC2</i> Exons 25 and 31 Are Very Unlikely to Cause Clinically Diagnosable Tuberous Sclerosis. <i>Human Mutation</i> , 2016, 37, 364-370.	2.5	16
43	Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile. <i>Modern Pathology</i> , 2021, 34, 264-279.	5.5	16
44	<i>TSC2</i> c.1864C>T variant associated with mild cases of tuberous sclerosis complex. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 771-775.	1.2	15
45	Mutational analysis of TSC1 and TSC2 in Danish patients with tuberous sclerosis complex. <i>Scientific Reports</i> , 2020, 10, 9909.	3.3	13
46	Hamartin Variants That Are Frequent in Focal Dysplasias and Cortical Tubers Have Reduced Tuberin Binding and Aberrant Subcellular Distribution In Vitro. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 1136-1146.	1.7	12
47	Functional and structural analyses of novel Smith-Kingsmore Syndrome-Associated MTOR variants reveal potential new mechanisms and predictors of pathogenicity. <i>PLoS Genetics</i> , 2021, 17, e1009651.	3.5	9
48	Analysis of TSC2 stop codon variants found in tuberous sclerosis patients. <i>European Journal of Human Genetics</i> , 2001, 9, 823-828.	2.8	5
49	Severe bleeding complications and multiple kidney transplants in a patient with tuberous sclerosis complex caused by a novel TSC2 missense variant. <i>Croatian Medical Journal</i> , 2017, 58, 416-423.	0.7	3